Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1245381714
Verified facts
CMS Open Payments records show Jessie A Fields, M.D. received $32.75 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.75 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.75 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 150 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 548 | 101 |
| Omeprazole | Omeprazole | 485 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 484 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 68 |
| Losartan Potassium | Losartan Potassium | 279 | 70 |
| Gabapentin | Gabapentin | 278 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 240 | 48 |
| Metformin Hcl | Metformin Hcl | 235 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 51 |
| Lisinopril | Lisinopril | 208 | 49 |
| Carvedilol | Carvedilol | 174 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 43 |
| Simvastatin | Simvastatin | 151 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 34 |
| Mupirocin | Mupirocin | 142 | 39 |
| Jardiance | Empagliflozin | 140 | 26 |
| Felodipine Er | Felodipine | 130 | 27 |
| Eliquis | Apixaban | 129 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 16 |
| Ciclopirox | Ciclopirox Olamine | 117 | 30 |
| Montelukast Sodium | Montelukast Sodium | 117 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 27 |
| Trazodone Hcl | Trazodone Hcl | 110 | 17 |
| Nifedipine Er | Nifedipine | 104 | 24 |
| Metformin Hcl Er | Metformin Hcl | 101 | 27 |
| Warfarin Sodium | Warfarin Sodium | 101 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 17 |
| Ozempic | Semaglutide | 97 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 95 | 32 |
| Glipizide Er | Glipizide | 92 | 23 |
| Latanoprost | Latanoprost | 91 | 23 |
| Ibuprofen | Ibuprofen | 88 | 19 |
| Ezetimibe | Ezetimibe | 86 | 14 |
| Januvia | Sitagliptin Phosphate | 84 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 13 |
| Furosemide | Furosemide | 83 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 73 | 18 |
| Meclizine Hcl | Meclizine Hcl | 72 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 71 | 20 |
| Chlorthalidone | Chlorthalidone | 70 | 19 |
| Famotidine | Famotidine | 69 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Entresto | Sacubitril/Valsartan | 63 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 24 |
| Azithromycin | Azithromycin | 57 | 36 |
| Novolog Flexpen | Insulin Aspart | 57 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 25 |
| Valsartan | Valsartan | 56 | 14 |
| Ammonium Lactate | Ammonium Lactate | 54 | suppressed |
| Glimepiride | Glimepiride | 54 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 52 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Prednisone | Prednisone | 51 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 12 |
| Torsemide | Torsemide | 49 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 11 |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 17 |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 17 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Desloratadine | Desloratadine | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.75 · 1 records | Novo Nordisk Inc | Ozempic | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error